Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview And Scope:
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size was estimated at USD 2070.35 million in 2022 and is projected to reach USD 2671.93 million by 2028, exhibiting a CAGR of 4.34% during the forecast period.
The Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Report 2023 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Chemotherapy Induced Nausea and Vomiting (CINV) Drugs utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2023 and 2030. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche, Mylan, Tesaro
Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Segmentation
By Type, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market has been segmented into:5-HT3 Inhibitors
NK1 Inhibitors
Other
By Application, Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market has been segmented into:
Highly Emetogenic Chemotherapy
Moderately Emetogenic Chemotherapy
Low Emetogenic Chemotherapy
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market.
Top Key Players Covered in Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market are:
Merck
Eisai
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro
Objective to buy this Report:
1. Chemotherapy Induced Nausea and Vomiting (CINV) Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Chemotherapy Induced Nausea and Vomiting (CINV) Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Type
5.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview Snapshot and Growth Engine
5.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview
5.3 5-HT3 Inhibitors
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2030F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 5-HT3 Inhibitors: Geographic Segmentation
5.4 NK1 Inhibitors
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2030F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 NK1 Inhibitors: Geographic Segmentation
5.5 Other
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2030F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Other: Geographic Segmentation
Chapter 6: Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market by Application
6.1 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview Snapshot and Growth Engine
6.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Overview
6.3 Highly Emetogenic Chemotherapy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2030F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Highly Emetogenic Chemotherapy: Geographic Segmentation
6.4 Moderately Emetogenic Chemotherapy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2030F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Moderately Emetogenic Chemotherapy: Geographic Segmentation
6.5 Low Emetogenic Chemotherapy
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2030F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Low Emetogenic Chemotherapy: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2016-2030F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 MERCK
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 EISAI
7.4 MUNDIPHARMA
7.5 QILU PHARMA
7.6 TEVA
7.7 NOVARTIS
7.8 HERON THERAPEUTICS
7.9 ROCHE
7.10 MYLAN
7.11 TESARO
Chapter 8: Global Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 5-HT3 Inhibitors
8.2.2 NK1 Inhibitors
8.2.3 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Highly Emetogenic Chemotherapy
8.3.2 Moderately Emetogenic Chemotherapy
8.3.3 Low Emetogenic Chemotherapy
8.3.4 Other
Chapter 9: North America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 5-HT3 Inhibitors
9.4.2 NK1 Inhibitors
9.4.3 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Highly Emetogenic Chemotherapy
9.5.2 Moderately Emetogenic Chemotherapy
9.5.3 Low Emetogenic Chemotherapy
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 5-HT3 Inhibitors
10.4.2 NK1 Inhibitors
10.4.3 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Highly Emetogenic Chemotherapy
10.5.2 Moderately Emetogenic Chemotherapy
10.5.3 Low Emetogenic Chemotherapy
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 5-HT3 Inhibitors
11.4.2 NK1 Inhibitors
11.4.3 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Highly Emetogenic Chemotherapy
11.5.2 Moderately Emetogenic Chemotherapy
11.5.3 Low Emetogenic Chemotherapy
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 5-HT3 Inhibitors
12.4.2 NK1 Inhibitors
12.4.3 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Highly Emetogenic Chemotherapy
12.5.2 Moderately Emetogenic Chemotherapy
12.5.3 Low Emetogenic Chemotherapy
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 5-HT3 Inhibitors
13.4.2 NK1 Inhibitors
13.4.3 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Highly Emetogenic Chemotherapy
13.5.2 Moderately Emetogenic Chemotherapy
13.5.3 Low Emetogenic Chemotherapy
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Analysis, Insights and Forecast, 2016-2030
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 5-HT3 Inhibitors
14.4.2 NK1 Inhibitors
14.4.3 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Highly Emetogenic Chemotherapy
14.5.2 Moderately Emetogenic Chemotherapy
14.5.3 Low Emetogenic Chemotherapy
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Scope:
Report Data
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Market Size in 2022
|
USD 2070.35 million
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs CAGR 2023 - 2030
|
4.34%
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Base Year
|
2022
|
Chemotherapy Induced Nausea and Vomiting (CINV) Drugs Forecast Data
|
2023 - 2030
|
Segments Covered
|
By Type, By Application, And by Regions
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
Key Companies Profiled
|
Merck, Eisai, Mundipharma, Qilu Pharma, Teva, Novartis, Heron Therapeutics, Roche, Mylan, Tesaro.
|
Key Segments
|
By Type
5-HT3 Inhibitors NK1 Inhibitors Other
By Applications
Highly Emetogenic Chemotherapy Moderately Emetogenic Chemotherapy Low Emetogenic Chemotherapy Other
|